Register

COURSE DESCRIPTION: 
We’re excited to welcome Karen Berger, Pharm.D., FASHP, FCCM, BCPS, BCCCP, for an in-depth session on the latest pharmacologic strategies in managing traumatic brain injury (TBI). During this session, Dr. Berger will review pharmacotherapy options for acute TBI management, evaluate current evidence supporting these treatments, and develop a treatment algorithm based on the latest guidelines. Whether you're a pharmacist, clinician, or healthcare professional involved in neurocritical care, this session will provide valuable insights to enhance your practice.

TARGET AUDIENCE:
Internal Medicine Physicians, Pharmacists, Physician Assistants, Residents,  Advanced Practice Registered Nurses, and all other interested healthcare providers

LEARNING OBJECTIVES:

• Assess pharmacotherapy options for the acute management of traumatic brain injury (TBI).
• Evaluate the evidence supporting the pharmacologic options for the treatment of TBI.
• Create a treatment algorithm based on current evidence and guideline recommendations.
   

FACULTY AND DISCLOSURES:

Karen Berger, Pharm.D., FASHP, FCCM, BCPS, BCCCP
Clinical Pharmacist
Baptist Health Boca Raton Regional Hospital
Boca Raton, Florida
Assistant Professor
Nova Southeastern University
Davie, Florida

Karen Berger, Pharm.D., FASHP, FCCM, BCPS, BCCCP, faculty for this educational activity, indicated that she is an advisor for Serb Pharmaceuticals. She is also a speaker for CSL Behring and Octapharma.  She has indicated that the presentation or discussion will not include off-label or unapproved product usage.  All of the relevant financial relationships have been mitigated.

John F. Rubin, M.D., FACP, director of this educational activity, has indicated that he is a shareholder in AstraZeneca and Bristol-Myers Squibb. All of the relevant financial relationships listed for this individual have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Disclosure Policy and Disclaimer

ACCREDITATION STATEMENTS AND CREDITS

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

This activity has been approved for 1 credit hour, CE Broker Course #20-1296402, by the Florida Boards of Medicine, Podiatry, Osteopathic Medicine and Physician Assistants.  

This activity has also been approved for 1 credit for Nurse Practitioners, Nurses, Pharmacists and Pharmacy Techs, Laboratory Personnel, Athletic Trainers and Respiratory Techs. Baptist Health South Florida CE Broker Provider #50-182.